Washington, DC 20231 U.S. Express Mail EL667443293US

TRANSMITTAL LETTER

Dear Sir/Madam:

We are transmitting herewith the attached:

- Information Disclosure Statement; 1)
- 2) PTO Form 1449;
- Sixty-one (61) references; 3)
- 4) Associate Power of Attorney; and
- Confirmation Postcard. 5)

Applicants do not believe any additional fees are due. However, if this is in error, the undersigned hereby authorizes the Commissioner to charge any deficiency or credit any excess fees to Deposit Account No. 50-0244.

Respectfully submitted,

AVENTIS PASTEUR, INC.

Date: December 4, 2001

Patrick J. Halloran Reg. No. 41,053

Aventis Pasteur, Inc. Patent Department Discovery Drive Swiftwater, Pennsylvania 18370 (570) 839-5446 Phone (570) 895-2702 Fax

HE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 11014-24)

In the	Application of:)			
	A. Pedyczak; P. Chong; C.D.Y. Sia)	Examiner: N	ot Assigned	
Serial) Art Unit: 10		546		
Filed:	April 10, 2001)		TECH	T
For:	Immunogenic Peptides Derived from Prostate-Specific Antigen (PSA) and Uses Thereof)		DEC 2 CENTER	ECE
вох г	INFORMATION DISCLOS	SURE S	TATEMENT	0° 2001 1 1600/290	

Asst. Commissioner for Patents Washington, D.C. 20231 U.S. Express Mail EL667443293US

Dear Sir:

Applicants respectfully submit this Information Disclosure Statement, PTO-1449 and copies of the reference cited therein. This Information Disclosure Statement is in compliance with the duty of candor as set forth in 37 C.F.R. § 1.56. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing of the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102 or §103.

1

CITED REFERENCES

U.S. Patents

- 1. 5,034,506
- 2. 4,598,049
- 3. 4,458,066
- 4. 4,401,796
- 5. 4,373,071
- 6. 5,843,456
- 7. 5,283,185

Foreign Patent Documents

- 8. WO 79/00475
- 9. WO 95/17211
- 10. WO 96/06627
- 11. WO 95/34323
- 12. WO 95/02415
- 13. WO 96/14831
- 14. WO 88/09336

Other Documents:

- 15. Carter, H.B. and Coffey, D.S., *Prostate* (1990) 16:39-48
- 16. Armbruster, D.A., Clin Chem (1993) 39:181-195
- 17. Wang, M.C., Kuriyama, M., Papsidero, L.D., Loor, R.M., Valenzuela, L.A., Murphy, G.P., and Chu, T.M., *Methods in Cancer Research* (1982) 19:179-197
- 18. Zietman, A.L., Shipley, W.L., and Willett, C.G., Cancer (1993) 71:959-969
- 19. Boon, T., Int. J. Cancer (1993) 54:177-180
- 20. Yam, Amer J Med (1974) 56:604
- 21. Sharief, F.S., et al., Biochem Biophys Res Commun (1992) 184:1468-1476
- 22. Van Etten, R.L., et al., *J Biol Chem* (1991) 266:9993-9999
- 23. Sharief, F.S., et al., Biochem Biophys Res Commun (1989) 180:79-86

- 24. Tailor, P.G., et al., Nucleic Acid Res (1990) 18:4928
- 25. Watt, K.W., et al., *Proc Natl Acad Sci USA* (1986) 83:3166-3170
- 26. Lundwall, A. and Lilja, H., FEBS Lett (1987) 214:317-322
- 27. Schultz, P., et al., Nucleic Acid Res (1988) 16:6226
- 28. Henttu, P. and Bihko, P., Biochem and Biophys Res Commun (1989) 1160:903-910
- 29. Lundwall, A., Biochem and Biophys Res Commun (1989) 162:1151-1159
- 30. Riegman, P.H., et al., Biochem and Biophys Res Commun (1989) 159:103-111
- 31. Klobeck, G., et al., Nucleic Acid Res (1989) 17:3981
- 32. Israeli, R.S., et al., *Cancer Res* (1993) 53:227-230
- 33. Deres, et al., *Nature* (1989) 342:561-564
- 34. Loing, et al., *J Immunol* (2000) 164(2):900-907
- 35. Baier, et al., *Immunobiology* (2000) 201:391-405
- 36. Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989) 6.3.1-6.3.6
- 37. Nielsen, P.E., et al., Science (1991) 254:1497
- 38. Chirgwin, et al., *Biochemistry* (1979) 18:5294-5299
- 39. Merrifield, J Am Chem Assoc (1964) 85:2149-2154
- 40. Chang, et al., *Nature* (1978) 275:615
- 41. Nichols and Yanofsky, Meth in Enzymology (1983) 101:155
- 42. Russell, et al., Gene (1982) 20:231
- 43. Bolivar, et al., Gene (1977) 2:9S
- 44. Messing, *Meth in Enzymology* (1983) 101:20-77

- 45. Vieira and Messing, Gene (1982) 19:259-268
- 46. Amann, et al., Gene (1988) 69:301-315
- 47. Studier, et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990) 60-89
- 48. Baldari, et al., *EMBO J* (1987) 6:229-234
- 49. Kurjan and Herskowitz, *Cell* (1982) 30:933-943
- 50. Schultz, et al., Gene (1987) 54:113-123
- 51. Hinnen, et al., *Proc Natl Acad Sci USA* (1978) 75:1929
- 52. Itoh, et al., *J Bacteriology* (1983) 153:163
- 53. Cullen, et al., *Bio/Technology* (1987) 5:369
- 54. Seed, B., *Nature* (1987) 329:840
- 55. Kaufman, et al., *EMBO J* (1987) 6:187-195
- 56. Sinkar, et al., *J Biosci (Bangalore)* (1987) 11:47-58
- 57. Smith, et al., *Mol Cell Biol* (1983) 3:2156-2165
- 58. Lucklow, V.A. and Summers, M.D., *Virology* (1989) 170:31-39
- 59. Salter, R.D. and Creswel, P., *EMBO J* (1986) 5:943
- 60. Deng, Y., Immunol (1997) 158:1507-1515
- 61. Milich, D.R., et al., *J Immunol* (1987) 139:1223-1231

Respectfully Submitted, AVENTIS PASTEUR INC.

Date: December 4, 2001

By:

Patrick J. Halloran Reg. No. 41,053